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Background
Augmenting a triptan regimen with another acute medi-
cation may be an indicator of suboptimal treatment.
Objectives
To quantify changes in headache-related disability for
migraineurs who added an acute treatment to an exist-
ing triptan regimen in a population-based sample.
Methods
AMPP study surveys were mailed to a sample of 24,000
persons with “severe headache” identified in 2004 and
followed annually through 2009. Eligible subjects had
ICHD-2 migraine treated with a triptan one year and
data in the subsequent year (a couplet). We examined 4
patterns of treatment: (a) consistent triptan treatment,
(b) adding another triptan, (c) adding an opioid or barbi-
turate or (d) adding an NSAID. Change in disability was
measured by MIDAS from the second to the first year
(negative change scores reflect improvement). Change
scores were modeled via ANOVA for all couplets and for
3 average headache-day frequency strata: low (0-4 days/
month), moderate (5-9 days/month), and high frequency
episodic/chronic migraine ([HFEM/CM]≥10 days/
month). ANOVAs were estimated for each possible add-
ing pattern relative to the consistent triptan use group.
The values of (b) represent change in MIDAS score.
Results
327 respondents met inclusion criteria and reported an
add pattern of interest. Adding another triptan was sig-
nificantly associated with increased headache-related
disability (b=10.4, p=.01) over one year, as was adding
an NSAID. The NSAID effect was greatest in those with
HFEM/CM compared to those with 0-4 days/month
(b=24.1, p=.03), and even greater for those with HFEM/
CM compared to 5-9 days/month (b=29.3, p=.02). Add-
ing an opioid or barbiturate was not significantly asso-
ciated with changes in disability.
Conclusion
Adding an opioid or barbiturate was not associated with
significant change in headache-related disability; how-
ever, adding a triptan or an NSAID was associated with
increased disability. The effects for NSAIDs were great-
est among the HFEM/CM group. Improvement in
options for migraine management is needed, especially
for persons with high frequency headache.
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